These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20865027)

  • 21. Pharmacogenetics of warfarin: current status and future challenges.
    Wadelius M; Pirmohamed M
    Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.
    Rhee S; Walsh K; Lewis D; Davis G; Smith KM
    Orthopedics; 2010 Nov; 33(11):828. PubMed ID: 21053849
    [No Abstract]   [Full Text] [Related]  

  • 23. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy?
    Goto S
    Circ J; 2010 May; 74(5):850-1. PubMed ID: 20424335
    [No Abstract]   [Full Text] [Related]  

  • 24. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
    Biss TT; Kamali F
    Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
    [No Abstract]   [Full Text] [Related]  

  • 25. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.
    McClain MR; Palomaki GE; Piper M; Haddow JE
    Genet Med; 2008 Feb; 10(2):89-98. PubMed ID: 18281915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 29. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose.
    Suarez-Kurtz G; Perini JA; Silva-Assunção E; Struchiner CJ
    Blood; 2009 Apr; 113(17):4125-6. PubMed ID: 19389892
    [No Abstract]   [Full Text] [Related]  

  • 33. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploiting common genetic variation to make anticoagulation safer.
    Genes for Cerebral Hemorrhage on Anticoagulation (GOCHA) Collaborative Group
    Stroke; 2009 Mar; 40(3 Suppl):S64-6. PubMed ID: 19150865
    [No Abstract]   [Full Text] [Related]  

  • 36. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic factors for warfarin dose prediction.
    Lippi G; Salvagno GL; Guidi GC
    Clin Chem; 2007 Sep; 53(9):1721-2. PubMed ID: 17712016
    [No Abstract]   [Full Text] [Related]  

  • 39. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.